A brief intervention for weight management in primary care: Study protocol for a randomized controlled trial by Lewis, A. et al.
A brief intervention for weight 
management in primary care: Study 
protocol for a randomized controlled 
trial 
Lewis, A. , Jolly, K. , Adab, P. , Daley, A. , Farley, A. , Jebb, S. , 
Lycett, D. , Clarke, S. , Christian, A. , Jin, J. and Aveyard, P. 
Published version deposited in CURVE May 2014 
 
Original citation & hyperlink:  
Lewis, A. , Jolly, K. , Adab, P. , Daley, A. , Farley, A. , Jebb, S. , Lycett, D. , Clarke, S. , Christian, 
A. , Jin, J. and Aveyard, P. (2013) A brief intervention for weight management in primary 
care: Study protocol for a randomized controlled trial. Trials, volume 14 (1): 393 
http://dx.doi.org/10.1186/1745-6215-14-393 
 
Additional note: 
Supplementary files are available 
from http://www.trialsjournal.com/content/14/1/393/additional . 
  
This is an open access article distributed under the terms of the Creative Commons 
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits 
unrestricted use, distribution, and reproduction in any medium, provided the original 
work is properly cited. 
 
 
 
 
CURVE is the Institutional Repository for Coventry University 
http://curve.coventry.ac.uk/open  
TRIALS
Lewis et al. Trials 2013, 14:393
http://www.trialsjournal.com/content/14/1/393STUDY PROTOCOL Open AccessA brief intervention for weight management in
primary care: study protocol for a randomized
controlled trial
Amanda Lewis1*, Kate Jolly2, Peymane Adab2, Amanda Daley3, Amanda Farley3, Susan Jebb4, Deborah Lycett5,
Sarah Clarke1, Anna Christian1, Jing Jin1, Ben Thompson1 and Paul Aveyard1Abstract
Background: Obesity affects 25% of the UK adult population but modest weight loss can reduce the incidence of
obesity-related chronic disease. Some effective weight loss treatments exist but there is no nationally available
National Health Service (NHS) treatment service, and general practitioners (GPs) rarely discuss weight management
with patients or support behavior change. Evidence shows that commercial weight management services, that
most primary care trusts have 'on prescription', are more effective than primary care treatment.
Methods/design: We propose a controlled trial where patients will be randomized to receive either the offer of
help by referral to a weight management service and follow-up to assess progress, or advice to lose weight on
medical grounds. The primary outcome will be weight change at 12-months. Other questions are: what actions do
people take to manage their weight in response to the two GP intervention types? How do obese patients feel
about GPs opportunistically discussing weight management and how does this vary by intervention type? How do
GPs feel about raising the issue opportunistically and giving the two types of brief intervention? What is the cost
per kg/m2 lost for each intervention? Research assistants visiting GP practices in England (n = 60) would objectively
measure weight and height prior to GP consultations and randomize willing patients (body mass index 30+, excess
body fat, 18+ years) using sealed envelopes. Full recruitment (n = 1824) is feasible in 46 weeks, requiring six sessions
of advice-giving per GP. Participants will be contacted at 3 months (postintervention) via telephone to identify
actions they have taken to manage their weight. We will book appointments for participants to be seen at their GP
practice for a 12-month follow-up.
Discussion: Trial results could make the case for brief interventions for obese people consulting their GP and introduce
widespread simple treatments akin to the NHS Stop Smoking Service. Likewise, the intervention could be introduced in
the Quality and Outcomes Framework and influence practice worldwide.
Trial registration: Current Controlled Trials ISRCTN26563137.
Keywords: Obesity, Brief intervention, Weight management, Primary care, Commercial weight management servicesBackground and rationale
Background
Obesity is an increasing problem in the UK, affecting
around 25% of the adult population and the preva-
lence is projected to double in the next half century
[1]. It is a major cause of morbidity and chronic disease,* Correspondence: amanda.lewis@phc.ox.ac.uk
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reproduction in any medium, provided the orparticularly increasing the risk of type II diabetes, cardio-
vascular disease and some cancers [2]. In addition, the dir-
ect economic cost in England is estimated at £4.2 billion
per year [1]. There is good evidence that moderate weight
loss (5 to 10% of initial body weight) among obese adults
leads to beneficial clinical outcomes, particularly reducing
the risk of diabetes [3]. However, there is a paucity of evi-
dence on the effectiveness of the diverse range of available
weight loss services [4], and whether these can be delivered
at a population level through primary care.td. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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apply these to obesity [5]. There are about nine million
smokers in England. In 2009/10 English general practi-
tioners (GPs)/family physicians made brief interventions
to motivate cessation to about 3 million people, prescribed
medication with brief support to 750,000, and another
750,000 attended the National Health Service (NHS) Stop
Smoking Service [6,7]. The NHS Stop Smoking Service
provides weekly behavioral support, either one-to-one or
in groups, with medication to assist cessation. The UK GP
pay-for-performance scheme, the Quality and Outcomes
Framework (QOF), rewards GPs for recording smoking
status of all patients and for intervening with patients with
smoking-related diseases or diseases exacerbated by smok-
ing (for example, asthma, diabetes). It is currently pro-
posed to extend this so that GPs would be rewarded for
intervening with all smokers, not just those with smoking-
related disease. This activity is based on evidence from ran-
domized controlled trials (RCTs) showing that GPs brief
interventions motivate cessation [8], and that referral for
more intensive behavioral support and medication en-
hances cessation rates over brief intervention alone [9,10].
Evidence from service evaluation of the NHS Stop Smok-
ing Service shows that outcomes achieved are those seen
in RCTs [11,12]. Taken together, brief interventions by
GPs, prescribing of cessation medication, and referral to
the NHS Stop Smoking Service make an important contri-
bution to population cessation rates and reduced preva-
lence in the UK.
Keeping a register of all adults with obesity in a prac-
tice is now also a clinical management area of the QOF.
However, GPs are required only to record weight and
there are no indicators related to interventions, even in
the case of obesity in diabetes. This reflects the lack of
evidence from RCTs for opportunistic intervention and
referral for weight management interventions that might
be practicable in primary care. Unlike for smoking, GPs
do not record whether or not they discuss weight man-
agement with their patients, there is no national surveil-
lance system for recording brief interventions and there
is no NHS weight management service, akin to the NHS
Stop Smoking Service.
Two recent RCTs investigated practicable interven-
tions for obesity management in primary care. In the
Birmingham Lighten Up trial, 740 patients were random-
ized to one of six interventions or minimal control [13,14].
The interventions were 3 month programs with Weight
Watchers (WW), Slimming World (SW), Rosemary Conley
(RC), Size Down (an NHS group program), GPs and phar-
macies. Dieticians trained GPs and pharmacists in weight
management. Using intention-to-treat (ITT) analysis with
(the conservative) baseline observation carried forward
(BOCF), GP and pharmacy care achieved similar weight
loss to the minimal control (1 kg at one year); that is, theywere ineffective. However, those receiving WW, SW and
RC lost 4 to 5 kg by 12 weeks, and at 1 year achieved 2 kg
(SW and RC) to 3.5 kg (WW) weight loss. These results
are similar to those from the trial by Jebb [15], where 772
participants randomized to 12 months WW or GP care
achieved a weight loss of 4.0 kg and 1.6 kg, respectively,
at 1 year. Over two-thirds of English primary care trusts
(PCTs) currently contract with commercial weight man-
agement services (CWMS), costing PCTs about £50 per
patient to provide a free (to the patient) 12-week treatment
course ‘on prescription’. An earlier systematic review con-
cluded that there was sufficient evidence of effectiveness
for WW but not the other main CWMS in the US [16].
Thus, CWMS, and WW in particular, provide an evidence-
based service analogous to the NHS Stop Smoking Service
and to which patients can be referred in the NHS.
In considering the nature of a GPs brief intervention
to induce weight loss in people who are obese, we exam-
ined several reviews [17,18] and considered data on current
practice and the views of GPs on intervening [19-23]. A
UK-based review recommended motivational interviewing
(MI) as an evidence-based strategy to engage and support
weight loss in patients in primary care. However, it noted
that training in MI takes at least 2 days and that 15 minutes
was the minimum time of counseling that has been found
to be effective [17]. Physicians reported several barriers to
intervening for weight management, but an important one
was time constraints, with the average 10-minute GP con-
sultation precluding use of MI. This means that current
evidence-based MI interventions are unlikely to be widely
implemented opportunistically and we therefore sought a
complementary and briefer strategy. Other barriers re-
ported include: lack of knowledge and lack of confidence
to address obesity [20,21], and beliefs derived from anec-
dotal observations that weight loss interventions are un-
successful [21]. The preferred intervention of GPs is brief
directive counseling, often aimed at increasing awareness
of health risks [21,22,24], an intervention not supported by
evidence from randomized trials [17,18]. Another key bar-
rier to intervention is fear that raising the topic of weight
management opportunistically would offend patients [22].
However, a study showed that almost all patients who are
obese recognize they have a weight problem, 95% want
to lose weight, and 84% wanted help from their doctor
to lose weight [25]. Patients who reported their doctor had
helped them previously were more likely to have been re-
ferred to weight loss programs, had exercise recommenda-
tions made, or discussed the health risks (in descending
order of helpfulness).
We also reviewed evidence of effective brief opportunis-
tic interventions to reduce problem drinking and motivate
smoking cessation [8,26]. It is clear from these reviews
that genuinely brief (1 minute) interventions can motivate
patients consulting for reasons unrelated to the behavior
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ing. We recently reviewed the trials on physician advice
for smoking cessation interventions, focusing on the key
components of either advice to stop smoking on health
grounds or offer of support on how to quit [27]. We found
that interventions that offered support were more ef-
fective at initiating attempts to quit (as well as supporting
abstinence) than was advice to quit on health grounds. We
concluded that patients are more likely to take action if
given an effective means to achieve their goal. This would
be predicted by PRIME theory, where behaviors are the
product of momentary desires which are in turn the prod-
uct of stimulus-induced images of possible futures to
which people feel attracted [28]. The Department of Health
built on this evidence to produce a 30-second intervention
for cessation: the 3As, ask (about smoking status), advise
(to stop), and act (referral for cessation support). We
propose an analogous intervention in weight management;
that is, we propose a 30-second intervention that concen-
trates on referral to an evidence-based weight manage-
ment service available currently in most of the NHS. In
this protocol, we call this an assistance-orientated inter-
vention and the traditional approach of raising the health
risks we call an advice-orientated intervention.
We therefore sought evidence that genuinely brief in-
terventions by GPs might motivate weight loss in people
who are obese. The US Behavioral Risk Factor Surveil-
lance System found that 42% of obese patients in 1996
reported that their physician had advised them to lose
weight (ever) [19,23]. People who had received advice
were more likely to have tried to do so (odds ratio (OR)
2.79 (2.53 to 3.08). By 2006 to 2008, 66% of obese pa-
tients had been told they were overweight by their phys-
ician [29]. Again, being told they were overweight was
strongly associated with attempting to lose weight in the
previous 12 months (OR 2.51 (1.74 to 2.88)). These data
support the hypothesis that GP even advice-orientated
brief intervention motivates weight loss, but bias or con-
founding could explain the association of recall of advice
and attempts to lose weight.
To our knowledge there are no previous RCTs to as-
sess the effectiveness of primary care led brief opportun-
istic interventions to support weight loss among people
who are obese and therefore propose the current trial to
assess an assistance-orientated intervention. This is based
upon evidence that referral to CWMS operating within
the NHS are effective, that suggesting referral takes only a
few seconds, that data from analogous brief interventions
on other behaviors suggest offering support is the most ef-
fective strategy, and there is some evidence to suggest that
brief weight loss advice from physicians could be effective.
In addition to referral to weight management services, we
propose that GPs offer patients in the intervention group
a follow-up appointment about a month after the initialconsultation. First, this signals to the patient that the GP
takes the issue of weight loss seriously and this may
prompt a person to take action. Second, weight monitoring
seems to be an important component of effective weight
loss interventions [30]. Third, we found in the Lighten Up
trial that some participants initially accepted a referral for
weight management but then did not take that up until
they were followed up, when a second referral was made.
Fourth, English NHS guidance suggests using orlistat in
patients who fail to lose weight despite adhering to an ap-
propriate weight loss intervention. In practice, prescription
of this pharmacotherapy is uncommon and we expect it to
be so in this trial. Finally, we will give GPs minimal training
to pass on a few tips on weight management that might be
helpful. We therefore propose to test an intervention of
several elements and it will not be possible to isolate the ef-
fectiveness of individual components. What we are propos-
ing testing is brief opportunistic intervention and active
engagement of GPs in supporting weight loss in patients
who are obese.
We also considered the nature of a comparison interven-
tion in the control arm. The most common response to-
wards a person with weight problems in primary care is
not to discuss this [22,24]. A reasonable comparator would
therefore be no intervention. On the other hand, asking a
person to participate in a trial related to weight manage-
ment and offering no intervention makes it clear that a
person is in the control arm. This could lead to differential
follow-up, which would threaten validity. In the Lighten
Up trial, people were more likely to agree to follow-up
weighing when a person had lost weight than when they
had not. The second most common response GPs make is
to advise that weight loss would benefit health - an advice-
orientated intervention [22,24]. We believe that offering
advice to lose weight on health grounds to the control
group does not reveal the random allocation to the
participant and may assist follow-up. The Lighten Up trial
showed that CWMS achieve higher weight loss than par-
ticipants who try to lose weight unassisted and therefore
there is a reasonable prospect of detecting a difference in
effect between our advice-orientated control intervention
and our assistance-orientated active intervention.
Rationale for the current study
Tobacco control interventions have successfully reduced
the prevalence of smoking in many societies. An import-
ant component is opportunistic interventions by the GP,
which are known to be effective in smoking and problem
drinking but not in obesity management. A recent sys-
tematic review identified no trials that examined whether
screening to identify overweight or obesity in adults and
brief intervention was effective [31]. This trial, the first to
our knowledge, will test whether opportunistic weight
management interventions are effective.
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demands on a GPs time and skills, which is a strategy
we have chosen deliberately. If successful, and if imple-
mented widely, it will increase the degree to which GPs
engage with weight loss and weight maintenance and
this may provide a base on which to build more complex
interventions. Further, the trial results could make the case
for brief opportunistic interventions for obese people con-
sulting their doctor and introduce widespread simple treat-
ments akin to the UK Stop Smoking Service. If brief
interventions are effective, this would make a strong case
to add brief interventions to the weight management com-
ponent of the QOF. It may influence practice worldwide,
as has been the case with brief interventions for smok-
ing cessation.
Objectives
Primary objective
1) To examine the effect of an assistance-orientated
(brief referral and review) versus advice-orientated
intervention (enhanced usual care) on mean weight
change at 12 months.
Secondary objectives
1) To examine the effect of an assistance-orientated
versus advice-orientated intervention on mean weight
change at 3 months (self-reported weight measure).
2) To examine the difference in the proportion of
participants in each intervention group who
achieved 5% and 10% weight loss at 12 months.
3) To examine how obese patients feel about discussing
their weight with their GPs when they have visited
for reasons other than their weight and how this
may vary by intervention type.
4) To examine what actions people take to manage
their weight, at 3 and 12 months, in response to the
two types of GP intervention.
5) To examine how GPs feel about raising the issue of
weight management opportunistically and giving the
two types of brief intervention both before and after
giving opportunistic interventions.
6) To assess the cost per kg, and per kg/m2, of the
weight lost to the NHS for the two types of
interventions.
Methods and study design
Summary of study design
Study design
A pragmatic RCT to compare 912 obese adults attending
their GP for reasons other than weight management who
receive an assistance-orientated intervention, with 912 ofthe same type of participants randomized to a control
group who receive an advice-orientated intervention.
Study duration
The total study duration will be 36 months. The timeline
(see Figure 1) illustrates the sequence and duration of all
study periods.
Participant participation
Each participant will be enrolled on the day of recruit-
ment and followed up for 12 months (see Figure 2 for
the study flow diagram).
Research sites
Sixty sites (that is, GP practices) within England. Add-
itional sites may be added if necessary to meet recruit-
ment targets.
Primary and secondary endpoints/outcome measures
We will assess the following outcomes in response to the
trial objectives outlined in section 2:
Primary outcome
1) Participants' weight change from baseline to 12 months.
Secondary outcomes
2) The mean change in participants' weight from
baseline to 3 months.
3) The proportion of participants who lose 5% and 10%
of their initial weight at 12 months.
4) Costs of the two types of intervention to calculate
the NHS cost per kg, and per kg/m2, lost.
Non-efficacy outcomes
5) Participants' reaction to the GP discussing weight
management, immediately after their GP appointment,
when they visited for reasons other than their weight.
6) The actions people take to manage their weight, at
3 months, in response to the two types of GP
intervention. This will include: attendance at the GP
to discuss weight; whether participants still continue
to manage their weight and the means they are
using to do so; or if they have abandoned a weight
management plan and why.
7) The actions people take to manage their weight
between 3 and 12 months following a brief
opportunistic intervention.
8) Participants’ thoughts about the opportunistic
intervention that was delivered and whether other
styles may have resulted in a different reaction than
the one experienced.
Study Task Month -6-0 1-3 4-6 7-9
10-
12
13-
15
16-
18
19-
21
22-
24
25-
27
28-
30
31-
33
34-
36
Document Preparation
e.g. ethics
Mar-
Aug
2012
Preparation (START 1st
Sept. 2012)
e.g. practice recruitment, 
GP & staff training
Sep-
Nov
2012
Dec-
Feb
2013
Patient recruitment & data 
collection (Visit 1)
Jan-
Feb 
2013
Mar-
May 
Jun-
Aug
Sep-
Nov
Dec
3 month follow up 
(telephone)
Apr-
May 
2013
Jun-
Aug
Sep-
Nov
Dec-
Feb
2014
Mar
12 month follow up (Visit 2) Jan-
Feb 
2014
Mar-
May
Jun-
Aug
Sep-
Nov
Dec
Finalisation 
e.g. data cleaning and 
verification, analysis and 
write up
Jan-
Feb 
2015
Mar-
May
Jun-
Aug
Figure 1 Sequence and duration of all study periods. GP, general practitioner.
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and appropriateness of, raising the issue of weight
management opportunistically and giving the two
types of brief intervention.
10) GPs thoughts about the brief intervention. This will
include exploring: why GPs felt as they did; whether
other brief interventions might be more or less
acceptable than the one they gave; and whether
these interventions might be suitable for all
overweight people, or only those with relevant
medical conditions.
11) GPs attitudes to making opportunistic interventions
and treating obese people before and after
participating in the trial.Measurements of outcomes
This section outlines the different stages of the study,
including how and when we will measure the above
outcomes.Visit 1 – Baseline There are three key purposes of this
visit. First is the identification of potential participants,
which is detailed below. At this point, we will ask to rec-
ord personal information from all patients, primarily to
assess eligibility for the trial, but to also update med-
ical records as an additional benefit to the GP practice
(Outcomes #1-3). Data to be collected by a research assist-
ant during this initial visit (pre-general practitioner con-
sultation) are as follows:Form 1 - BWeL Trial Screening Form (These data are to
identify potential participants; the research team will ask to
keep a copy of this if a person is eligible for the study but
declines participation. This is to compare the characteristics
of people who participate to those who do not. In addition
one copy will be passed to the GP to update records).
 Name (to identify the record) Note: The research
team will not keep this data for anyone who is
eligible but not willing to participate in the trial, in
line with the Data Protection Act, 1998.
 Date of birth (to establish age and for identification)
 Main language spoken ([optional] for trial purposes
and to update GP record)
 Ethnic group ([optional] for trial purposes and to
update GP record)
 Height, weight and percentage body fat (to assess
eligibility for the trial and to constitute baseline
measures if so, and to update GP medical records)
 Gender
Form 2 - Written evidence of consent (for eligible and
willing patients only).
Form 3 - BWeL Participant Contact Sheet (These data
will only be collected for patients who are eligible and
consent to be part of the BWeL trial).
 Address, including postcode
 Telephone number(s)
 Email address(s)
All consenting patients visiting GP 
during recruitment have their 
height and weight measured and 
are screened for trial eligibility
Excluded:
- <18 years of age
- BMI <30 (or <25 for South Asian 
population groups) and low body fat
- Pregnant women/intending to 
become pregnant during trial period
-Unwilling to participate & be 
randomized
- Visiting GP for weight 
management
- Currently (or within past 3 months) 
participating in weight management 
program (including 
pharmacotherapy or bariatric 
surgery)
- Unable to speak/understand 
English
Randomized (n=1,824)
Allocated to intervention group
(assistance-orientated) at baseline 
assessment (n=912)
Assistance-orientated (practical 
support) intervention:
- GP offers patient referral to a free 
commercial weight management 
service currently available in the NHS 
(i.e. a 12 week treatment course of 
Slimming World / Rosemary Conley)
- 1 month after enrolment: follow up 
appointment with GP to have weight 
re-assessed and review progress. 
Re-referral can be made if first referral 
was not taken up, or Orlistat 
prescribed if the treatment program 
was unsuccessful.
Allocated to control group (advice-
orientated) at baseline assessment 
(n=912)
Advice-orientated (medical advice) 
intervention:
- GP advises patient of the health 
risks associated with being obese 
and the benefits of weight loss.
3 months (after enrolment): Follow up 
telephone call to assess patient’s 
actions taken to manage their weight 
since enrolment and self reported 
weight
12 months (after enrolment): Follow up 
assessment (in clinic or home visit if 
required) to objectively asses patient‘s 
weight and establish any actions taken 
to manage their weight between 3 and 
12 months.
3 months (after enrolment): Follow up 
telephone call to assess patient’s 
actions taken to manage their weight 
since enrolment and self reported 
weight
12 months (after enrolment): Follow up 
assessment (in clinic or home visit if 
required) to objectively asses patient‘s 
weight and establish any actions taken 
to manage their weight between 3 and 
12 months.
Figure 2 Study flow chart. BMI, body mass index; GP, general practitioner; NHS, National Health Service.
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patients to join the trial. If a patient is willing to participate,
written consent to participate in the trial and random-
ization will take place immediately, as detailed below.
The third purpose is to measure participants’ reactions
to the GP discussing weight management, immediately
after their GP appointment, when they visited for rea-
sons other than their weight (Outcome #5). The research
assistant (RA) will ask all participants, upon exit of their
appointments, for their randomization card and enve-
lope (and withdrawal card if applicable). The random-
ization card will ask participants to rate the helpfulness
and the appropriateness of the GPs very brief interven-
tion on five-item Likert-type scales that the GP and/or
RA will ask the participant to complete; this will becarried out confidentially in the RAs room. Where pa-
tients have not been randomized, the RA would explain
that the GP does not feel it is suitable for them to be in-
volved in the trial at this time and, therefore, they have
not been enrolled; GPs will be asked to record why the
patient was not randomized (see below).
Follow-up telephone call at 3 months (after enrolment)
A researcher will contact all participants via telephone
(or by alternative methods such as email, post or text
message if telephone contact is not possible) 3 months
after their initial appointment to assess what actions
they have taken, if any, to manage their weight since the
appointment (Outcome #6). We will also assess if partic-
ipants are continuing to manage their weight and through
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weight, we will ask why and record this on a simple check-
list of possible reasons. We will ask participants to stand on
their scales and read out their weight or report a recently
obtained weight (Outcome #2). We will also ask how many
contacts participants have had with their GP where the
prime purpose was weight management. Pregnancy status
will also be updated to ensure weight data are valid.
Visit 2 - follow-up appointment at 12 months (after
enrolment) A researcher will telephone all participants
to arrange for them to meet with an RA, for a 12-month
follow-up appointment, at their own GP surgery. The
main purpose of the visit is to objectively measure the
participant’s weight (Outcomes #1 and 3). As a precau-
tionary measure (that is, in case the participant does not
attend their clinic follow-up appointment, or if partici-
pants decline to attend), during the booking telephone
call the researcher will collect data on whether and what
methods of weight management the participants have
used/continued to use since the 3 month follow-up
(Outcome #7). In addition, we will ask participants to
stand on their scales and read out their weight or report
a recently obtained weight. Pregnancy status will also be
updated to ensure weight data are valid.
As the follow-up appointment holds no therapeutic
value, we will pay those participants who attend a small re-
imbursement (£10.00) to cover the cost and inconvenience
of attending.
Before GPs have started their trial involvement We
will ask all GPs to complete a questionnaire containing
a few short questions about their attitudes to making
opportunistic interventions and treating obese people
(Outcome #11).
After GPs have finished their trial involvement We
will ask all GPs to complete a short questionnaire about
their attitudes to making opportunistic interventions
and treating obese people, using the same questions as
used ‘before the GPs trial involvement’ (Outcome #11). In
addition, we will ask about their views of the appropriate-
ness and helpfulness of giving brief interventions (Out-
come #9). We will subsequently briefly interview, via
telephone, up to 30 participating GPs to examine their
thoughts about the brief intervention (Outcome #10);
GPs will be purposively selected based on the range of re-
sponses to the post-trial questionnaire to represent a
range of reactions to delivering the intervention. The
interview will explore why GPs felt as they did and
whether other brief interventions might be more or less
acceptable than the one they gave and whether these in-
terventions might be suitable for all overweight people or
only those with relevant medical conditions. We willcontact selected GPs as soon as possible after receiving
their questionnaire to minimize forgetting.
After completion of participant recruitment Similar
to above, we will interview, via telephone, up to 30 par-
ticipants based on the range of responses to the post-
consultation questionnaire (see Visit 1) and ask them
about why they responded as they did and whether an-
other style of opportunistic intervention might engender
a different reaction (Outcome #8). We will contact se-
lected participants as soon as possible after the consult-
ation to minimize forgetting.
After trial completion Costs of the two types of inter-
vention will be assessed to calculate the NHS cost per kg,
and per kg/m2, lost (Outcome #4).
Loss to follow-up
We will make a maximum of three attempts to contact
participants before abandonment, using multiple means
and trying different times. More than this could be seen
as harassment. If participant’s data is missing we will use
ITT analysis with BOCF for the primary outcome assess-
ment (see below – Description of Statistical Methods).
Study participants
Overall description of study participants
In total, 1,824 obese adults in England attending their
GP for reasons other than weight management; 912 in
each of the two treatment groups (see Sample size calcu-
lations below).
Inclusion criteria
Any patient, during recruitment, that:
 Is identified with a body mass index (BMI) ≥30
(or ≥25 for South Asian population groups) and
excess body fat.
 Is ≥18 years of age.
 Consents to participate and comply with study
procedures.
Exclusion criteria
The participant may not enter the study if any of the fol-
lowing apply:
 Pregnant or intending to become pregnant during
the trial period (that is, the next 12 months).
 Currently or within the past 3 months participated
in a weight management program (including
pharmacotherapy or bariatric surgery).
 Unable to understand and speak English sufficiently
to give informed consent and complete the research
assessments.
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 The GP deems it inappropriate to make an
opportunistic intervention on weight management.
This includes personal medical reasons known to
the GP, such as an eating disorder, or reasons related
to the consultation (for example, the patient has
become distressed and it would seem insensitive to
make such an intervention at that time). If the GP
does not consider it appropriate, then the patient
will not be enrolled and randomized into the trial
(see Randomization of participants below).
Study procedures
Informed consent
The Recruitment of participants section below specifies
who will take informed consent and how and when it
will be taken.
Study assessments
The Measurement of outcomes section above outlines
the different stages of the study, including each assess-
ment and time points. The sections below outline add-
itional study procedures (that is the recruitment of GP
practices and participants and the randomization, enrol-
ment and withdrawal procedures).
Recruitment of GP practices
We will invite practices to participate without restriction
as to the type of practice.
Recruitment of participants (including screening, eligibility
and baseline assessment)
The trial will involve about 60 GP practices within
England, where we propose recruiting our participants.
On arrival at the practice, the receptionist will provide a
participant information leaflet (PIL) to each patient at-
tending for a GP consultation during that recruitment
session. The PIL would inform patients that everyone vis-
iting a GP during that session will be asked, by a RA
before their appointment with the GP, if they (that is
the RA) could briefly take a few measurements to
update the practice medical records (as identified in
Visit 1 - Baseline, Form 1, above). The PIL will also
state “This is part of a study that is taking place at the
practice; the researcher will tell you more. The researcher
will also ask for your name, date of birth, ethnicity, and
the language you speak. This will be done in a private
consultation room and take less than 10 minutes. If you
do not want to see the researcher, you do not have to.
It will not affect the care we give you in practice today
or in the future”. In practices where patients check-in
for their appointment via an automated computer sys-
tem upon arrival, rather than seeing a receptionist, the
PILs will be positioned by the check-in system, and theon-screen message will be programmed to ask the patient
to take one.
To check the patient’s health, the RA will measure
height and weight and percentage body fat of willing pa-
tients in a vacant consultation room using medically ap-
proved and validated weighing scales (Tanita portable
body composition analyser, model SC 240 MA); the RA
will ask participants to remove excess clothing (for ex-
ample, coats and large jumpers) and shoes to increase
accuracy of body weight, body fat and height. On the ad-
vice of our GP consumer group, we will ask receptionists
booking patients for this session to advise patients that
this health check will be taking place and ask them to at-
tend about 10 minutes prior to the appointment if pos-
sible. This is designed to help prevent disruption to the
GP appointment schedule and provide reassurance to
the patient that they have time to speak with the RA and
will not miss or delay their appointment.
During the height, weight and body fat assessment, the
RA will collect socio-demographic data (see Measurement
of outcomes [Visit 1, Baseline] for details), so that the re-
search team can examine whether the population enrolled
were a biased selection of all those attending and, as a
secondary benefit, to update the GP records. The RA
will invite patients meeting the trial eligibility criteria
(see Inclusion and Exclusion criteria above) to participate
“in a study about people’s reactions and response to GPs
discussion of their weight”; the RA will explain the trial to
interested patients and answer any questions that they
may have, as well as provide them with a trial patient in-
formation sheet (PIS) for future reference. If the patient is
willing to participate, the RA will seek immediate written
informed consent to participate in the trial (that is, trial
consent) prior to their appointment with the GP. It is in-
herent in the nature of brief opportunistic advice that pa-
tients cannot be given warning of this or it ceases to be
opportunistic.
We will ask to keep anthropometric and demographic
data of patients who decline to participate in the trial.
The researcher will record evidence of verbal consent
for this on the Trial Screening Form.
Participant recruitment rate
We anticipate nine adults will consult per GP per ses-
sion, of whom at least 25% will be obese and 75% of
these will agree to participate in the study. In reality, the
population of consulters is likely to be biased towards
people with obesity because of its association with chronic
disease, so the 25% is likely to be an underestimate. In tri-
als of brief intervention for smoking cessation, recruit-
ment rates (where they could be assessed) were high
(100% [32], 93% [33], 88% [34], 89% [35], 87% [36], 96%
[37], 92% [38], 90% [39]). As nearly all patients who are
obese believe they have a weight problem and 84% would
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75% uptake is achievable. These figures would require us
to attend 1,054 sessions and, with the staffing available,
this could be achieved in 46 weeks to obtain the sample
size of 1,824. Each GP will have intervened for about six
sessions, which appears reasonable. The approach outlined
here with the RA ‘in the waiting room’ was the most com-
mon approach used in other trials of brief interventions.
Randomization of participants
Participants will be randomized to a treatment arm at the
baseline visit, which will be conducted at their own GP
practice (see Measurement of outcomes [Visit 1, Baseline]
for details). The RA will give eligible patients who are will-
ing to participate in the trial an opaque A4 sealed enve-
lope, which will contain a color-coded randomization
card. The envelopes will be numbered in sequence. We
will use block randomization of randomly sequenced
blocks of 2 and 4 stratified by GPs, which will balance in-
dividual consulting styles. The trial statistician will be re-
sponsible for the production of randomization schedule,
prior to recruitment.
The RA will ask patients to give the sealed envelope to
their GP upon entering their consultation. The card in-
side the sealed envelope will reveal to the GP, but not
the patient, which intervention to deliver. We will ask
GPs not to open the randomization envelope until they
are satisfied that it is suitable for the patient to be in-
cluded in the trial (that is, after they have addressed the
patient’s primary reason for visiting them and feel that it
would be clinically appropriate to offer a brief interven-
tion at this time to this patient - see Exclusion criteria
above; once the randomization envelope is opened then
the patient has been enrolled in the trial. It would
undermine the ability of the study to detect differences
between the arms if we enrolled participants who did
not receive an intervention. Attached to the outside of
each randomization card envelope will be a detachable
‘patient withdrawal card’. The RA will discretely write
the patient’s weight and BMI on the back of the with-
drawal card before handing the sealed envelope to them
so that the GP will be aware of their up-to-date mea-
surements, if required, during the consultation. Further-
more, there will be a tick box option on the card for
GPs to select if they did not randomize the patient in to
the trial, indicating that the person has not been ran-
domized and therefore not enrolled. The tick box will
indicate the reason for non-enrolment (that is, clinically
inappropriate, not appropriate in the consultation or
special reasons). If ‘special reasons’ is selected, the GPs
will be asked to state why, if they can without break-
ing patient confidentiality, in the space provided. The
sealed envelope and withdrawal card would be returned
to the RA by the patient after their consultation (seeMeasurement of outcomes [Visit 1, Baseline]) and the en-
velope will then be replaced at the top of the random-
ization envelope pile for use by the next appropriate
potential participant.
To examine the fidelity of the intervention, the brief-
intervention component of a proportion of consultations
by each GP will be audio-recorded (see Treatment pro-
viders below). If an audio recording is required, a card
will be attached to the randomization card inside the
randomization envelope reminding the GP to turn on
the audio-recorder at the appropriate time during the con-
sultation. If a patient has not consented to audio-recording
of the brief intervention, the GP will be alerted to this by a
sticker on the randomization envelope.
Unblinding
Due to the nature of this trial, it is necessary for the GPs
and RAs to be aware of the patient’s treatment group al-
location to ensure the correct intervention is provided.
Thus, these personnel cannot be blinded to treatment.
Patients and the members of the research team that will
conduct follow-up assessments, however, will be blinded
to treatment allocation.
As this is an open label trial the issue of unblinding
the clinicians caring for the patient does not arise.
Withdrawal criteria
Trial withdrawal Participation in the trial is based upon
patients consenting to take part. At the time of consent
(see Recruitment of participants above) participants will
be given a PIS to keep, which will provide details of what
they should do if they no longer want to take part in the
trial. The PIS will state that participants are free to with-
draw from the trial at any point without it affecting their
care and that they would not be contacted again by the
research team. The PIS will include a telephone number
for participants to contact the researchers for this or
other reasons. Patients who have withdrawn will not be
replaced but we will use their data up to the point that
they withdrew unless they request that we do not do so.
There are no withdrawal criteria other than patient or
GPs request to withdraw.
Treatment withdrawal The main treatment is the offer
of advice or support for weight loss from the GP. Partici-
pants cannot withdraw from receiving these interven-
tions as they are a natural part of the consultation. Of
course, it is possible that participants may choose not to
return to the GP for further discussion of their weight.
They may also choose not to attend a weight manage-
ment intervention and, having initially attended, may
choose not to complete a course of treatment. Such de-
cisions will have no affect on the follow-up of partici-
pants in the trial.
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The end of study is the date of the last date of follow-up
for the last patient. The appropriate standard operating
procedure (SOP) (Primary Care Clinical Trials Unit [PC-
CTU] SOP TM23), outlining the necessary procedures
for trial closure, as written by the Clinical Trials & Re-
search Governance Office, University of Oxford (CTRG),
will be adhered to.
Interventions
Intervention arms
After GPs have dealt with the patient’s original present-
ing complaint(s), they will briefly deliver one of two
treatments, which the participant is randomly allocated
to. The treatments include:
An ‘assistance-orientated’ treatment (intervention)
The GPs assistance-orientated treatment (that is, practical
support) is aimed to last no more than a few seconds:
“Did you know that the best way to lose weight is to go to
Slimming World? I can refer you now for free on the NHS
if you would like.” The choice of weight management ser-
vice will mainly be determined by availability in the local
area. In the Lighten Up trial, WW, RC, and SW each per-
formed better than the control group [13].
If the person agrees to referral to the CWMS, the GP
will ask the participant to make an appointment at re-
ception to return in a month: “I know it can be difficult
to lose weight, so I’d like you to return in a month to
see how you’re getting on”. If the participant wants to
try weight loss without assistance, the GP might say: “It’s
fine for you to try to lose weight on your own but I
know it’s hard. Would you make an appointment to re-
turn in a month to see how you are getting on?” This
provides an opportunity to re-refer those who accepted
referral but did not attend, refer those who tried to lose
weight on their own but did not do well, prescribe orli-
stat to those who have followed the treatment program
but not succeeded (in line with NICE guidance), and it
lets the patient know their doctor is taking this seriously
[30]. If the participant wants to discuss this with their
GP, the GP will encourage the participant to make an-
other appointment to do so (English GPs have 10 minutes
per consultation).
Outside the context of the trial, we would envisage
that the GP would make a referral to the weight man-
agement service in the same way s/he makes referrals
to other services. We could envisage a system of direct
booking, where the availability and days/times of local
services are shown online on the GPs computer. How-
ever, because referral to weight management is uncom-
mon, our GPs and patient representatives advised us it
would be better to ask the research team to do this. We
will aim for the RA in the practice to hold details of localgroups that are available and make a booking immediately,
to capitalize on the patient’s impulse to act. If this is not
possible, we will arrange to telephone the participant at the
earliest convenience with details of the options available.
The commercial weight management referral scheme
typically consists of 12 vouchers enabling patients to at-
tend classes for free (or use the online equivalent for
anyone who does not want to or cannot attend groups).
These services encourage weight loss via a healthy life-
style such as increased physical activity, a reduced fat
diet and offer group counseling for motivation and be-
havior change, with target setting for weight, activity,
and energy intake. Intervention group participants will
get 12 free sessions but are usually encouraged by the
group leader to continue their involvement by paying, al-
though in practice a minority do so. (We will obtain data
on length of enrolment in the service from service pro-
viders and also from participants at follow-up.) Re-referral
will be allowed within the rules operating in the PCT. Full
details of the behavioral change techniques used by the
three common services are available in the Lighten Up trial
protocol [13].
An ‘advice-orientated’ treatment (control)
After considering the difficulties of a no-intervention con-
trol arm, we propose an advice-orientated treatment (that
is, medical advice) such as: “It is important to lose weight
because it would reduce your chances of getting heart
problems, diabetes, and arthritis”. Other than no interven-
tion, this appears to be the most common brief interven-
tion offered currently and there is evidence that it is
associated with attempts to lose weight. We believe it is
polite and respectful and patients seem to find it helpful
that their doctor passes on this kind of advice [25].
Treatment providers
As noted above, the primary treatment (that is, delivery
of either an assistance- or advice-oriented intervention)
will be made by the participant’s GP. All GPs will receive
trial specific training prior to commencing the study at
their practice. We will train GPs using academic detail-
ing methods, an established evidence-based technique
for changing behavior [40]. The principal method of de-
livery will be via video-tutorials designed specifically for
this trial, which will be available to GPs on a dedicated
website before and during the trial. Each tutorial will be
available to be viewed independently, rather than all having
to be viewed at once, and also as downloadable audio files
for alternative convenience. A similar approach has re-
cently been established for smoking cessation (see www.
NCSCT.co.uk/VBA); we intend to adopt a similar model.
The training video will consist of eight modules, lasting
up to 2 hours in total: 1) the case for intervening in obesity;
2) the BWeL trial; 3) medical advice arm; 4) practical
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port arm part 2: the review session at 1 month; 6) medical
advice arm: the dedicated weight consultation; 7) practical
support arm: the dedicated weight consultation; and
8) summary. The modules will be designed to address
perceived barriers of the GPs to intervene in weight man-
agement. These barriers are that weight management is
ineffective, which we will address by showing evidence
that health risk is continuously associated with degree of
overweight and that reduced weight reduces risk, even if
the visible change is imperceptible. The barriers will also
be addressed by evidence on the effectiveness of the com-
mercial providers in the NHS referral schemes. We will
also aim to address the lack of knowledge and hence con-
fidence to intervene on weight management. This will be
addressed firstly by reassuring GPs that we are not
expecting them to undertake nutritional and physical ac-
tivity assessments, and that the prime aim of the review
session is reweighing, which is probably a key component
of a weight loss intervention [30], and offer of referral/
re-referral to the weight management services. Never-
theless, we recognize that patients might ask their GP
for specific weight loss advice and our GP advisors were
struggling to say more than “eat less, do more”. The
modules will train GPs to deflect detailed questions about
nutrition. We will provide GPs with a self-help guide
published by the British Heart Foundation called ‘So You
Want To Lose Weight…For Good’. We are not aiming to
get GPs involved in behavioral change strategies or give
particular or detailed advice, only allay concerns that
might arise from offering patients a 10-minute review
to discuss weight management. If there is any uncer-
tainty about treatment delivery (for example, intervention
content and methods of delivery) then GPs will be able to
contact the research team for clarification.
To examine the fidelity of the interventions, we will
seek the permission of both participants and GPs to
audio-record the brief intervention component of a pro-
portion of consultations (n = 5) by each GP. Most GPs will
be familiar with recording their consultations as part of
their training and most patients agree to this. To examine
for evidence of consultation distortion, we will take the
first 30 participants who have been recorded and compare
the immediate post-consultation ratings of helpfulness
and appropriateness to those not recorded. If evidence of
distortion is found, we will not continue the recordings.
Fidelity in the intervention group will be assessed by re-
cording whether or not an offer of referral was made and
whether or not there was supporting discussion (for ex-
ample, encouragement to attend, advice on the superiority
of the service over trying alone). Fidelity in the control
group will be assessed on whether advice was given that
linked weight loss to improved health and that no offer of
referral to weight management was made.Participants in the assistance-orientated intervention
(that is, practical support) group will be offered referral
to an evidence-based CWMS available in the NHS; for
example, SW or RC. Immediately after the GP appoint-
ment, RAs at the GP practice will provide the intervention
group participants with their weight management referral
packs and assist booking the participant’s first appoint-
ment. Group leaders of these CWMS undertake rigorous
weight management training through their organization
and are expected to follow standard procedures.
Safety
There is no reason to assume that this study will lead to
an excess of adverse events. The treatment consists of ad-
vice from the GP and offer of referral to a weight manage-
ment service, neither of which seem likely to create harm.
We are aiming to recruit participants who are not specific-
ally motivated to lose weight and therefore intend to keep
participant burden to a minimum. Therefore, we will not
monitor the occurrence of adverse events by trial arm.
We recognize that follow-up of participants requires
us to behave sensitively and that, in a trial of this size,
some participants will suffer serious health events or other
misfortunes that will come to light in a follow-up tele-
phone call. To ensure that future follow-up attempts are
appropriate, we will log these events in the critical events
log of the case report form (CRF).
Statistics and analysis
Number of participants
The primary outcome will be weight change at 12 months.
The following figures assume a 70% follow-up achieved in
the Lighten Up trial and use the (conservative) ITT BOCF
figures. We assume that 30% in the CWMS arm will take
up referral and achieve the mean loss seen in our trial of
the same intervention at 1 year (3.46 kg with BOCF for
missing outcome data) and that 10% in the control arm
will try to lose weight and achieve the mean loss seen in
the Lighten Up trial (1.16 kg). The Prospective Studies Col-
laboration showed that obese people observed over a few
years lose a little weight on average, at about 50 g/year [2].
These assumptions give mean weight loss of 1.07 kg versus
0.16 kg. The standard deviation for weight change was
about 6.0 kg in both our Lighten Up and the Jebb trial
[14,15]. On these assumptions, with 90% power and 5%
type I error, we would need to randomize 912 people to
each arm: 1,824 in total.
Description of statistical methods
Primary outcome
The primary outcome of change in weight at 12 months
will be analyzed by ITT BOCF for missing data. We will
calculate mean and standard deviations of weight change
at 12 months and compare the intervention arm with the
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for baseline weight. This will be the primary analysis for
the trial. A pre-specified sub-group analysis will examine
the effect of gender, age (as a continuous variable), ethnic
group, deprivation score derived from postcode and BMI.
Residual plots will be used to examine model assumptions
and where necessary transformations and/or bootstrapping
will be used to address gross departure from normality.
The possibility of GP effects will be explored via a random
effects coefficient in the model.
Secondary outcomes
The difference in mean weight change at 3 months will
be compared between the two treatment arms using
ANCOVA adjusting for baseline weight with BOCF for
missing data. Proportions of participants who achieve at
least 5% or 10% weight loss at 12 months will be reported
using descriptive statistics and the difference between two
arms and 95% CI will be calculated. The costs of the two
interventions will summarized as £ per kg and £ per kg/m2.
Non-efficacy outcomes
For participant’s reaction (assessed by two Likert scale
questions) to the GP discussion of weight management
when they visited for reasons other than their weight,
total score will be calculated and compared between two
arms using a t-test or a Mann–Whitney-U test if the data
are too far from normality. The median for each question
will be calculated and compared using a Mann–Whitney-
U test.
Whether participants take any actions to manage their
weight at 3 months and between 3 and 12 months follow-
ing a brief opportunistic intervention reported by partici-
pants as a yes/no variable will be presented as frequencies
and compared between the two arms using a chi-square
test. What actions participants took will be coded as a
three-category variable (that is, effective action, some ac-
tion and no action) and compared for the difference be-
tween arms using proportional odds logistic regression.
Reactions of GPs to raising the issue of weight manage-
ment opportunistically and giving the two types of brief
intervention will be summarized by presenting the frequen-
cies of each response to question 1, 2 and 7 of GP post-trial
questionnaire part 2 in a bar chart. Total score will be cal-
culated by summing questions 3 and 4 for the reaction of
GPs to advise to lose weight and summing questions 5 and
6 for the reaction of GPs to offering support. These two
total scores will be compared using a paired t-test.
Only summary statistics will be presented by interven-
tion arms for the following non-efficacy outcomes:
 Change from pre-trial to post-trial in the frequencies
of each response to the first 11 questions of GP
questionnaire part 1 and the mean percentage forquestion 12 regarding GP attitudes to making
opportunistic interventions and treating obese people.
 Frequency of each category of reasons for not trying
to lose weight given by participants. Total number of CWMS sessions taken.
The qualitative data on responses to the intervention
(as identified in Data handling and record keeping below)
will be analyzed using framework analysis. This approach
is a relatively quick method of qualitative enquiry that al-
lows deductive exploration based on the aims and objec-
tives of the interview. A thematic framework for analysis
will be constructed prior to interview and unanticipated
themes arising during interview will be added to the frame-
work as appropriate. Data will be sorted and summarized
under theme and subtheme headings from which the range
and diversity of attitudes and experience will be summa-
rized and explanatory linkages explored.
Other
Fidelity of the intervention will be assessed using a rat-
ing scale for key elements in the brief intervention types
and summarized as a score (see Treatment providers
section above for details of data). These are descriptive
process data and will not be compared by arm.
A trial statistical analysis plan will be drawn up before
the recruitment starts.
Ethics
Participant confidentiality
The identification data of patients will be required for the
registration process. The study coordination centre will pre-
serve the confidentiality of all data obtained which are to be
kept by the BWeL research team in compliance with the
Data Protection Act (DPA) 1998 and PC-CTU SOP DM 01
04 “Data Management”, 23-03-2012; this includes data of
trial participants. No personal identification data will be
kept for patients who are eligible but refuse to participate;
the research team will only keep their non-identifiable data
to compare the characteristics of those who are eligible and
do take part with those who are and do not. The trial man-
agement team will monitor confidentiality and consent will
be sought from patients for the study sponsor or their dele-
gates, members of the study team, regulatory authorities
and the PCT to have direct access to patient medical re-
cords. All data obtained from patients who are not eligible
to participate in the study will be provided to the GP prac-
tice only; the BWeL research team will not keep any of
these data as they are not needed.
Other ethical considerations
Ethics approval
The study co-ordination centre obtained approval from the
National Research Ethics Service (Reference 13/SC/0028).
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recommendations for physicians involved in research
on human subjects adopted by the 18th World Medical
Assembly, Helsinki 1964 and later revisions.
Patient consent
See Recruitment of participants section above for details.
Data handling and record keeping
Data handling, record keeping and retention
The trial is being run as part of the portfolio of trials in
the PC-CTU. The data management will be run in ac-
cordance with the trials unit SOPs, which are fully com-
pliant with the DPA and Good Clinical Practice (GCP).
The source documents for the study will be the Trial
Screening Form and Participant Contact Sheet (see Visit 1,
above), CRFs and questionnaires, which will be securely
held in locked, fire-protected storage facilities. These will
be transferred from the site of the research visits to the
university, and consent will explicitly be sought from
participants to do so. The study database will be securely
held and maintained by the PC-CTU. On completion of
the trial and data cleaning, the study documentation, in-
cluding patient identifiable information will be trans-
ferred to a secure, GCP compliant, external archiving
facility, where they will be held either until the end of the
trial and then destroyed or indefinitely after the end of
the trial to allow participants to be recruited into further
studies or additional follow-up, and patients will be asked
to consent to either of these options. The database will
be made anonymous and a secure compact disc contain-
ing the link between identification number and patient
identifiable information will be stored in a secure archiv-
ing facility.
Data access and quality assurance
Data will be kept in accordance with the DPA. The SOPs
of the trials unit will be followed, which are designed
to protect patient confidentiality. Patient identifiable
information will be available to the person conducting
follow-up as it is important that these data are known to
them. Otherwise, confidentiality will be maintained and
no-one outside the study team will have access to either
the CRFs or the database.
Case report forms
The secure online database will incorporate an online
CRF; however, there will also be a paper copy of CRFs.
In the context of the GP surgery it will not be possible
to use an online CRF. In this case the paper CRF will be
completed and data will be copied to the online version
at a later date. As previously mentioned, paper CRFs
will be securely held in locked, fire-protected storage
facilities.Study management
The day-to-day management of the study will be coordi-
nated by the University of Oxford research team; re-
searchers will be provided with study specific training and
be able to contact the research team for clarification.
Study personnel
See Additional file 1 for study personnel details.
Trial steering committee
A Trial Steering Committee (TSC) will be convened to
provide overall supervision of the trial and ensure its
conduct is in accordance with the principles of GCP and
the relevant regulations. The TSC will agree the trial
protocol and any protocol amendments; any amend-
ments to the protocol will be made in accordance with
the PC-CTU SOP TM SO_P9 “Protocol Amendments”
27-02-2012. Furthermore the TSC will provide advice to
the investigators on all aspects of the trial. The TSC will
be chaired by Professor Mike Lean, (Head of Depart-
ment of Human Nutrition at the University of Glasgow).
Rod Taylor (Associate Professor at Penninsula Medical
School), Sarah Hardcastle (Senior Lecturer at the Uni-
versity of Brighton), Dr Isabelle Mantella (Clinical Lec-
turer at the University of Birmingham) and Mr and Mrs
Fletcher (patient representatives who used the Lighten Up
service) have agreed to be members. Dr Ghada Zoubiane
(Programme Manager, Medical Research Council) has also
agreed to join the committee.
Data monitoring committee
We do not propose that a data monitoring and ethics
committee would be useful, based on examples from
http://www.ct-toolkit.ac.uk/ as this is an unblinded study
with no substantial risk and no early termination rules.
The final decision was made by the TSC, who agreed
that it would not be useful for this trial and that they
would adopt the role if required.
Quality control and quality assurance procedures
The study will be conducted in accordance with the
current approved protocol, ICH GCP, relevant regulations
and PC-CTU SOPs. The PC-CTU has in place procedures
for assessing risk management for trials which will outline
the monitoring required. The monitoring will be carried
out by the PC-CTU Quality Assurance Manager or equiva-
lent. The investigators and all trial-related site staff will re-
ceive appropriate training in GCP and trial procedures.
Regular monitoring will be performed according to
ICH GCP. Data will be evaluated for compliance with the
protocol and accuracy in relation to source documents
where possible. Following written SOPs, the monitors
will verify that the clinical trial is conducted and data
are generated, documented and reported in compliance
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requirements.
The PC-CTU Trial Management Committee (TMC) will
be responsible for the monitoring of all aspects of the trial’s
conduct and progress and will ensure that the protocol is
adhered to and that appropriate action is taken to safe-
guard participants and the quality of the trial itself. The
TMC will be comprised of individuals responsible for the
trial’s day-to-day management (for example, the Chief In-
vestigator, trial manager, statistician, data manager) and
will meet regularly throughout the course of the trial.
Financing and insurance
Funding
The Medical Research Council (National Prevention Re-
search Initiative – Phase 4) is funding this study.
Participant payments
We will compensate those participants who attend their
12 month follow-up appointment at their GP practice; a
small honorarium fee (£10.00) to cover the cost and in-
convenience of attending.
GP payments
GPs will be paid, through NHS service support costs, for
their time to deliver the intervention, which currently is
not part of standard routine. These reimbursements are on
a scale determined by the Primary Care Research Network.
Negligent harm
The University has arrangements in place to provide for
harm arising from participation in the study for which
the University is the Research Sponsor.
Non-negligent harm
The University has arrangements in place to provide for
non-negligent harm arising from participation in the
study for which the University is the Research Sponsor.
Publication policy
We will present the results to the TSC prior to publica-
tion. The Investigators will be involved in reviewing
drafts of the manuscripts, abstracts, press releases and
any other publications arising from the study. Members
of the TSC will be listed and their contribution acknowl-
edged, as will the funding source (the Medical Research
Council NPRI – Phase 4). Authorship will be determined
in accordance with the ICMJE guidelines and other con-
tributors will be acknowledged. The funders have no
contribution to make on decisions on publication.
Discussion
The aim of this trial is to test the effectiveness of a brief,
opportunistic intervention for weight management inprimary care; to our knowledge, no trials to date have in-
vestigated this issue. If successful, trial results could make
the case for brief interventions for obese people consulting
their GP and introduce widespread simple treatments akin
to the NHS Stop Smoking Service. Likewise, the interven-
tion could be introduced in the QOF and influence prac-
tice worldwide.
Throughout this protocol we identified some challenges
that we envisaged we might encounter whilst undertaking
the trial, and how we proposed dealing with them. Such
challenges included: participant identification and recruit-
ment; training GPs about the importance of weight man-
agement and how to intervene for the purposes of this
trial; assessing the fidelity of the interventions; and ways
to ensure high patient follow-up rates. Here we briefly dis-
cuss a few of the key challenges that the research team
have encountered since the trial started; we believe this in-
formation will provide valuable insight for future trials of
this nature, and especially about weight management in
primary care.
Timely completion of GP training
In a number of cases, GPs have failed to start and/or
complete the online trial specific training prior to com-
mencing the study at their practice. As a result, we have
had to delay the start of the study in their practice and
ensure that the training is fully completed by a rear-
ranged date. As highlighted in the Treatment providers
section above, GP training is delivered via a trial-specific
online training video; the video consists of eight tutorials
that are designed to address the perceived barriers of
GPs to intervening in weight management. Each tutorial
can be viewed independently, rather than all having to
be viewed at once, and are also downloadable as an
audio file for alternative convenience. The total length of
the training video is up to 2 hours.
GPs felt that they did not have sufficient time to under-
take the training, and advised that they had to address
‘more important’ issues within ‘spare’ practice time. Some
GPs had also started but not completed the training; they
apparently felt slightly overwhelmed by the detail and
length of the first tutorial. As a result, the research team
asked practice managers at the site initiations to warn
GPs of this and to book a slot in their diary for them to
complete the training. This solved the problem in new
practices.
Fidelity checks of intervention delivery
As highlighted in the Other ethical considerations sec-
tion above, we examine the fidelity of a proportion of
each GP session via audio-recordings to check that in-
terventions are being delivered to protocol and in accord
with that randomly allocated. The audio-recordings have
been invaluable, far more than anticipated in fact, as we
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ample, GPs forget key elements of the intervention, GPs
offer additional interventions to participants in the con-
trol arm, and some GPs describe the research study (the
content of the advice given in both arms of the trial) be-
fore delivering the intervention that the participant was
randomly allocated to; this appears to occur more when
GPs are new to research. The recordings have allowed
us to pick up these problems and coach GPs to deliver
the interventions to protocol early in their involvement
in the trial and while the researcher and GP are in prac-
tice together. Subsequent recordings of the same GPs
demonstrate that this feedback and coaching has been
successful and rectified previous mistakes. Furthermore,
prior to GPs commencing their initial BWeL sessions,
the researchers now undertake a brief question and an-
swer session with them to check their understanding of
what they need to do, confirm their understanding of how
the two interventions differ, check how they would respond
to common scenarios and clarify any concerns they may
have. Clarification and advice is given where needed.
Practical issues for the recruiters in practice
As detailed in the Recruitment of participants section
above, researchers conduct a screening session for pa-
tients visiting the participating GP while they are waiting
for their appointment to measure body weight, height
and percentage body fat. These measurements are essen-
tial to identify eligible patients for the trial. However, it
soon became apparent that some mainly elderly patients
had problems even undertaking the screening because
their frailty and unsteadiness meant they could not be
easily weighed or have their body fat assessed. In that
context, it seemed probably inappropriate to offer weight
loss advice anyway leading to exclusion on clinical grounds
after seeing the GP. There was some discussion as to
whether an age limit should be introduced to prevent situ-
ations of this kind. We decided originally against this and
reaffirmed our decision not to use an upper age limit as
it was frailty not age that was the issue. However, we ini-
tiated a ‘common sense’ rule to make life more comfort-
able for the researchers doing the screening “Could the
patient be weighed accurately or not?” If a patient is un-
stable on the scales or has to be supported, then we can-
not get an accurate measure and therefore we cannot
establish whether they are eligible and screening need
not be attempted or can be quickly aborted. These patients
are not counted in numbers of people screened as they
could not be measured accurately. Where researchers have
concerns about a patient’s frailty the researcher now po-
litely directs them to accept not being screened. Our obser-
vation is that many patients want to please, so if we make
it clear that we are very happy not to weigh them they are
happy with that.Finally, regular monitoring of all operating procedures
and discussions with the research team have ensured that
if and when things do not happen as planned, then we can
act upon them quickly by designing and implementing
suitable changes and whilst it still can be corrected.
Trial status
Participant recruitment began in June 2013.
Additional file
Additional file 1: Study personnel sheet.
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